about
Distinctive attributes of β-lactam target proteins in Acinetobacter baumannii relevant to development of new antibioticsPotent inhibitors of LpxC for the treatment of Gram-negative infectionsPyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infectionsNovel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolatesPyridone-conjugated monobactam antibiotics with gram-negative activitySiderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteriaDiscovery of a Selective Covalent Inhibitor of Lysophospholipase-like 1 (LYPLAL1) as a Tool to Evaluate the Role of this Serine Hydrolase in MetabolismEstimation of aqueous solubility of organic compounds with QSPR approach.Markov modeling reveals novel intracellular modulation of the human TREK-2 selectivity filter.Chemotypic coverage: a new basis for constructing screening sublibraries.Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.Assessment of the consistency of medicinal chemists in reviewing sets of compounds.Novel Methods for Prioritizing "Close-In" Analogs from Structure-Activity Relationship Matrices.Molecular Basis for Inhibition of the Na+/Citrate Transporter NaCT (SLC13A5) by Dicarboxylate Inhibitors.Evaluation and Characterization of Trk Kinase Inhibitors for the Treatment of Pain: Reliable Binding Affinity Predictions from Theory and Computation.Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.Smoothened antagonists for hair inhibition.Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications.Collaborating to improve the use of free-energy and other quantitative methods in drug discovery.Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.Molecular similarity measures.Pantolactams as androgen receptor antagonists for the topical suppression of sebum production.Hit-directed nearest-neighbor searching.Delineating the role of cooperativity in the design of potent PROTACs for BTK.Molecular similarity measuresStrategies for the identification and generation of informative compound setsChemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitorsHeterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agentsInducing protein-protein interactions with molecular gluesCyclic Peptide Design Guided by Residual Dipolar Couplings, J-Couplings, and Intramolecular Hydrogen Bond AnalysisTRPA1 ankyrin repeat six interacts with a small molecule inhibitor chemotype
P50
Q27675361-FFFECA2D-A7B6-4932-B9D6-A1D5F56FAE77Q27676242-07F4F97D-2220-4423-B352-A6B5D3E87713Q27676790-E92D4D07-D493-493C-8DB2-A82FAF6C5376Q27684005-439C14B1-6C9E-4C64-96F0-6901CC123745Q27684802-A6189C5F-DCFF-4554-B610-AD0A5366E501Q27689683-9FEB0FCA-2BF3-47C9-B059-2221E60D5407Q27717747-607D9F31-C744-4F58-8529-7CEE5AFBA88AQ30733668-9B79C76C-C64C-4073-9CDF-3DBCE87668B6Q30849395-EB498131-F18D-488B-8795-FA97A3272107Q33444130-395B959E-B610-44E2-A150-BBA0D71554B9Q33517279-0271BE77-E849-458F-B417-E569EF43C0A9Q35888315-D6BEF95B-D8CC-451A-BCF5-D2A336E701CBQ38705325-A7C2316A-1E55-4A42-BA34-2CDF63811BABQ38800864-C4EB86B3-F45B-454C-8E92-7867AC40DDA2Q38893670-3A312F3E-9D01-400D-9AE3-6DFE1601FED0Q42183441-0B271464-0A35-4B04-AA12-9226D4C9AA37Q42824755-7D9E9839-4377-4A18-92E8-04369E31A688Q46315631-2ED981E0-A922-4286-9402-055C5CD11E2FQ48006451-555A620C-350F-4C37-9CD1-F15549C5A5F5Q48750921-D61FBB92-5086-4603-B1BA-CCFA2F90F97AQ51661566-58D5A9ED-159A-469D-BDC8-69C6CFEE8624Q51766062-A5960FD4-50B7-4DFA-B43C-C253D01A2060Q51980909-5D03854B-43FA-47CD-8D34-DDFBAF255942Q64940546-15657ABB-750E-46B4-97B1-31E8409150ACQ80083251-BF661AE3-A65B-4DC9-8334-A5C4946E7A62Q80083261-3197441E-F35A-41A3-90E2-ABD7AAF62793Q85920044-85DE0CCD-4AE2-48A8-A6B4-3D42082CFF82Q87419477-61EC17F3-62A3-4DCE-92CC-0EF836698E20Q89448065-74DCB0F0-14EA-4B58-ACEC-B3DF46EE1D57Q90863853-DE5C9ABF-2930-4AE3-9F94-13690D2E4A61Q93079706-604CFBBF-E867-434B-91BD-840AA5BB7BE0
P50
description
researcher
@en
wetenschapper
@nl
name
Veerabahu Shanmugasundaram
@en
Veerabahu Shanmugasundaram
@nl
type
label
Veerabahu Shanmugasundaram
@en
Veerabahu Shanmugasundaram
@nl
prefLabel
Veerabahu Shanmugasundaram
@en
Veerabahu Shanmugasundaram
@nl
P106
P31
P496
0000-0003-0566-6779